article thumbnail

FTC’s Proposed Non-Compete Rule: A Step in the Right Direction for Health Care and Biotechnology

Bill Of Health

Banning non-compete clauses may help to promote competition and innovation in biotechnology and health care. Currently, there is a high degree of knowledge concentration in new and evolving technologies in the biotechnology sector.

article thumbnail

ChristianaCare Spins Out New Gene Editing Company, CorriXR Therapeutics

HIT Consultant

What You Should Know: – ChristianaCare recently announced it has spun out its first commercial biotechnology private startup company, named CorriXR Therapeutics. The CorriXR Therapeutics team includes experienced biotechnology executives and world-renowned scientists and clinicians. The executive team is led by Eric Kmiec, Ph.D.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why We Should Care About the Move from Saliva to Living Cells in Precision Medicine

Bill Of Health

While the Moderna-Merck intervention classifies as a regulated drug or therapy, it is not a stretch of the imagination to map this type of dynamic onto a non-therapeutic service offering like 23andMe. It seems, in the near term, that the “who” would probably be a venture-backed biotechnology company — a corporate actor.

article thumbnail

Highlights from Petrie-Flom Center Discussion on Neuroscience and Cannabis

Bill Of Health

Panelists discussed these topics during a recent webinar hosted by the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics. By Minsoo Kwon The legalization of cannabis has raised ethical, regulatory, and scientific questions. This article highlights key points made during the conversation.

article thumbnail

BPA-free Does Not Mean Bisphenol-Free and How Regulators are Grappling to Deal with It

Bill Of Health

Regulating bisphenols , a class of endocrine disrupting chemicals, has been challenging due to “ regrettable substitution. Regulating bisphenols , a class of endocrine disrupting chemicals, has been challenging due to “ regrettable substitution. BPA is one of many Endocrine Disrupting Chemicals (EDCs).

article thumbnail

A Brief Quantum Medicine Policy Guide

Bill Of Health

These technologies can act as privacy enhancing techniques (PET) to ensure privacy and compliance with regulations like HIPAA and GDPR. There is no specific regulation for quantum technology in healthcare, though the European Declaration on Quantum Technologies acknowledges its importance. The regulatory landscape in the U.S.

article thumbnail

Introductory Editorial — Critical Psychedelic Studies: Correcting the Hype

Bill Of Health

Dr. Devenot is also an affiliated researcher with Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Neşe Devenot, PhD is a Senior Lecturer in the University Writing Program at the Johns Hopkins University.